INTRODUCTION {#s1}
============

Variceal rebleeding is a frequent and severe complication in cirrhotic patients. Patients who survive an episode of acute variceal hemorrhage are at increased risk of rebleeding and death. The median rebleeding rate in untreated individuals is approximately 60% and the mortality rate is 33% within 1-2 years of the hemorrhage \[[@R1]--[@R3]\]. Pharmacotherapy, endoscopic variceal ligation (EVL), and the transjugular intrahepatic portosystemic shunt (TIPS) are the recommended interventions for the prevention of variceal bleeding. Drug therapy, more specifically nonselective β-blockers or a combination of isosorbide mononitrate (ISMN) and nadolol, has been found to reduce portal pressure and prevent variceal rebleeding \[[@R4], [@R5]\]. Ligation is reported to be more effective at reducing patient mortality than sclerotherapy \[[@R6]\]. In addition, EVL achieves variceal obliteration with fewer endoscopic sessions and has been found to be effective in controlling active variceal bleeding \[[@R7]--[@R10]\]. The TIPS procedure is a minimally invasive, image-guided intervention used for secondary prevention of bleeding and as salvage therapy in acute bleeding \[[@R11]\]. TIPS were created with Wallstents (Schneider, Inc., Plymouth, Minnesota) using standard techniques described elsewhere, and effectively control bleeding in patients with refractory variceal hemorrhage \[[@R12], [@R13]\].

Several randomized controlled trials (RCTs) have reported the differences in efficacy between these interventions in the control of esophageal variceal bleeding. Although drug therapy was stated to be as effective as EVL in current studies \[[@R14], [@R15]\], it has also been reported that combination therapy is more effective than EVL or drug therapy alone for reducing the risk of rebleeding, although the effect on mortality was unclear \[[@R15], [@R16]\]. Moreover, there is evidence to suggest that TIPS is more effective at reducing rebleeding than drug therapy or EVL \[[@R17]--[@R19]\]. However, whether the TIPS is more effective than combination therapy (pharmacotherapy and EVL) has not been investigated. Therefore, we performed a meta-analysis of randomized trials to assess the efficacy of combination therapy (pharmacotherapy and EVL) compared with pharmacotherapy, EVL, or TIPS alone in the prevention of rebleeding and mortality in this study.

RESULTS {#s2}
=======

Characteristics of individual studies {#s2_1}
-------------------------------------

We identified 2153 publications from the electronic databases (Figure [1](#F1){ref-type="fig"}), of which 516 were excluded as duplicates and 1358 were excluded based on selection criteria. This resulted in 279 articles, which were independently read by two authors. Eventually, ten studies involving 1076 patients were included in our meta-analysis \[[@R20]--[@R29]\]. The characteristics of each individual study are presented in Table [1](#T1){ref-type="table"}.

![Summary of trial identification and selection](oncotarget-08-57399-g001){#F1}

###### The characteristics of each individual study

  Study                     Year   Country       Patients (C/M)   Mean age (C/M)             Male/female   Alcohol (C/M)   Viral (C/M)   Child score (C/M)   Combination therapy   Monotherapy   Follow-up time (months)                                                                                                  
  ------------------------- ------ ------------- ---------------- -------------------------- ------------- --------------- ------------- ------------------- --------------------- ------------- -------------------------------------------------- --------------------------------------------------------------------- -----------
  Lo \[[@R26]\]             2000   China         60/62            53± 11/51± 12              94/28         17/20           41/41         11/12               12/18                 19/22         Nadolol 60mg/day, 1-2 bands                        1-2 bands                                                             22/21
  De la Pena \[[@R27]\]     2005   Spain         43/37            60/60                      60/20         27/26           112/8         6/6                 25/20                 2/11          Nadolol 58mg/day, EVL                              NA                                                                    17.5/17
  Jain \[[@R28]\]           2006   American      61/67            NA                         NA            NA              NA            26/24               23/37                 12/6          Propranolol 114.3mg/day, EVL                       NA                                                                    NA
  Kumar \[[@R29]\]          2009   India         88/89            42(14)/41(14)              153/24        33/30           13/20         35/26               31/34                 10/15         Propranolol 120mg/day, ISMN 40mg/day, 2-10 bands   2-10 bands                                                            15/15
  Lo (a) \[[@R30]\]         2009   Taiwan        47/46            52±11/50±12                77/16         15/17           28/26         13/14               20/25                 14/7          Terlipressin 4mg/day, 4 bands                      Terlipressin 1 mg/6h for 5 days                                       NA
  Lo (b) \[[@R31]\]         2009   Taiwan        60/60            54±10/52±11                87/33         21/15           31/40         20/21               29/31                 11/8          Nadolol 40 mg/day, ISMN 20mg/day, EVL              Nadolol 40 mg/day, ISMN 20mg/day                                      22.3/22.7
  Garcia-Pagan \[[@R32]\]   2009   Spain         80/78            57±12/56±11                118/40        39/42           25/18         16/18               46/42                 18/18         Nadolol 36mg/day, ISMN 36mg/day, EVL               Nadolol 36mg/day, ISMN 36mg/day                                       14.4/15.3
  Garcia-Pagan \[[@R35]\]   2010   Spain         31/32            49±6/52±10                 44/19         20/22           5/4           NA                  16/16                 15/16         Propranolol 55mg/day, ISMN 25mg/day, EVL           e-PTFE--covered stents: 10mm                                          14
  Luo \[[@R33]\]            2015   China         36/37            50.78±13.61/ 49.53±14.02   43/30         2/4             30/26         NA                  25/24                 12/12         Propranolol, 65.4 mg/day, 4-6 bands                e-PTFE--covered stents: 10mm                                          20.9/22.8
  Holster \[[@R34]\]        2016   Netherlands   35/37            54/56                      41/31         18/13           1/7           13/13               18/19                 4/5           Terlipressin 6-12mg/day, 4.3 bands                 Balloon-expandable stent: 8 mm in 21 patients, 10 mm in 10 patients   23

C/M, combination therapy/monotherapy; EVL, endoscopic variceal ligation; ISMN, isosorbide mononitrate; e-PTFE, extended polytetrafluoroethylene; NA, not available.

Quality of the included studies {#s2_2}
-------------------------------

The risk of bias in the included studies was strictly evaluated. Details of methodological approach are presented in Table [2](#T2){ref-type="table"}.

###### The risk of bias in the included studies

  Study                     Year   Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias
  ------------------------- ------ ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------
  Lo \[[@R26]\]             2000   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  De la Pena \[[@R27]\]     2005   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  Jain \[[@R28]\]           2006   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  Kumar \[[@R29]\]          2009   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              High risk
  Lo (a) \[[@R30]\]         2009   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  Lo (b) \[[@R31]\]         2009   Low risk                     Low risk                 Unclear                                  Low risk                         Low risk                  Low risk              Low risk
  Garcia-Pagan \[[@R32]\]   2009   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  Garcia-Pagan \[[@R35]\]   2010   Low risk                     Low risk                 Unclear                                  Unclear                          Low risk                  Low risk              Low risk
  Luo \[[@R33]\]            2015   Low risk                     Unclear                  Unclear                                  Unclear                          Low risk                  Low risk              Unclear
  Holster \[[@R34]\]        2016   Low risk                     Low risk                 Unclear                                  Low risk                         Low risk                  Low risk              Unclear

Overall mortality {#s2_3}
-----------------

When assessing the effect on overall mortality (as shown in Figure [2](#F2){ref-type="fig"}), combination therapy did not significantly differ from EVL alone in a fixed-effects model (RR=0.62, 95%CI: 0.36-1.08, I^2^=0.0%, P=0.592). Compared to pharmacotherapy alone, combination therapy also had no significant effect on overall mortality in a fixed-effects model (RR=1.05, 95%CI: 0.68-1.63, I^2^=0.0%, P=0.523). Similarly, combination therapy versus TIPS did not show a statistically significant difference in a random-effects model (RR=1.39, 95%CI: 0.92-2.09, I^2^=53.7%, P=0.115).

![Forest plot of overall mortality](oncotarget-08-57399-g002){#F2}

Mortality caused by variceal bleeding {#s2_4}
-------------------------------------

We also assessed the effect on mortality caused by variceal bleeding (summarized in Figure [3](#F3){ref-type="fig"}), and found that combination therapy did not significantly differ from EVL alone in a fixed-effects model (RR=0.43, 95%CI: 0.15-1.25, I^2^=0.0%, P=0.785). Compared to pharmacotherapy alone, combination therapy also had no significant effect on mortality caused by variceal bleedingin a fixed-effects model (RR=0.42, 95%CI: 0.17-1.06, I^2^=0.0%, P=0.542). However, TIPS resulted in a significant decrease in mortality caused by variceal bleeding when compared to combination therapy in a fixed-effects model (RR=5.66, 95%CI: 1.02-31.40, I^2^=0.0%, P=0.490).

![Forest plot of mortality caused by variceal bleeding](oncotarget-08-57399-g003){#F3}

Recurrence of bleeding {#s2_5}
----------------------

We next evaluated the effect on recurrence of bleeding (summarized in Figure [4](#F4){ref-type="fig"}). Combination therapy resulted in a significant decrease in the recurrence of bleeding (RR=0.57, 95%CI: 0.41-0.79, I^2^=0.0%, P=0.418), when compared to EVL alone in a fixed-effects model. In comparison to pharmacotherapy alone, combination therapy also significantly decreased the recurrence of bleeding in a random-effects model (RR=0.65, 95%CI: 0.48-0.88, I^2^=60.7%, P=0.079). However, TIPS significantly decreased bleeding recurrence when compared to combination therapy in a fixed-effects model (RR=9.42, 95%CI: 2.99-29.65, I^2^=0.0%, P=0.542).

![Forest plot of rebleeding](oncotarget-08-57399-g004){#F4}

Recurrence of bleeding from esophageal varices {#s2_6}
----------------------------------------------

Finally, we assessed the effect on recurrence of bleeding from esophageal varices (summarized in Figure [5](#F5){ref-type="fig"}). Combination therapy did not significantly differ from EVL alone in a random-effects model (RR=0.59, 95%CI: 0.33-1.06, I^2^=63.7%, P=0.064). Compared to pharmacotherapy alone, combination therapy resulted in a significant decrease in the recurrence of bleeding from esophageal varices in a fixed-effects model (RR=0.58, 95%CI: 0.40-0.85, I^2^=0.0%, P=0.760). However, TIPS significantly decreased esophageal bleeding recurrence in comparison to combination therapy in a random-effects model (RR=2.20, 95%CI: 1.22-3.99, I^2^=75.1%, P=0.045).

![Forest plot of rebleeding from esophageal varices](oncotarget-08-57399-g005){#F5}

Publication bias {#s2_7}
----------------

No publication bias was observed for any of the outcomes based on the symmetry of the funnel plots, as shown in [Supplementary Figures 1--4](#SD1){ref-type="supplementary-material"}. The results of the Egger\'s test indicated no significant difference in any of the outcomes: overall mortality (Bias=0.514, 95%CI: -3.291-2.263, P=0.675), blood-related mortality (Bias=0.339, 95% CI: -2.393-3.072, P=0.763), recurrence of bleeding (Bias=1.280, 95%CI: -2.257-4.816, P=0.421), and recurrence of bleeding from esophageal varices (Bias=1.724, 95%CI: -1.785-5.233, P=0.262).

DISCUSSION {#s3}
==========

Despite the administration of vasoactive drugs \[[@R30], [@R31]\], ligation of varices often combined with drugs \[[@R14]\], or placement of a TIPS, there is still a 15% to 20% mortality rate within 30 days, and an increased risk of rebleeding (up to 25%) within six weeks \[[@R32], [@R33]\]. Currently in the clinic, most studies have revealed that EVL is an appropriate substitute for endoscopic sclerotheapy, as EVL achieves variceal obliteration quicker, thereby resulting in lower rebleeding rates \[[@R16], [@R34], [@R35]\]. The combination of pharmacotherapy and EVL could be more effective than monotherapy (pharmacotherapy and EVL alone). In addition, TIPS is a new therapeutic modality for variceal bleeding with recognized results \[[@R36], [@R37]\]. Accordingly, this study evaluated the clinical benefit of pharmacotherapy plus EVL compared with pharmacotherapy and EVL alone, and TIPS.

This meta-analysis evaluated the clinical benefit of combination therapy, pharmacotherapy and EVL, compared with that of pharmacotherapy and EVL alone. Combination therapy was found to be more effective than monotherapy (pharmacotherapy and EVL alone) at preventing rebleeding, which was consistent with other studies \[[@R15], [@R38], [@R39]\]. The rationale for combining drug therapy with EVL is that they act through different mechanisms; EVL reduces variceal size, and drug therapy lowers portal pressure \[[@R20]\]. However, when assessing rebleeding from esophageal varices, the benefit of combination therapy was only observed in comparison to pharmacotherapy alone, and not with EVL. This could be attributed to the number of patients and events in analysis of the two subgroups. There was no statistically significant difference between combination therapy and monotherapy in the all-course mortality rate or mortality caused by bleeding. Similar findings have been reported by Thiele et al., who suggested that the combination of EVL and medical therapy could reduce the risk of rebleeding, but not overall mortality \[[@R38]\]. Gonzalez et al. provided conflicting evidence, suggesting that combiantion therapy can reduce the risk of mortality \[[@R39]\]. This difference in findings could be attributed to the sample size.

We provide evidence that TIPS was superior to combination therapy in reducing the risk of rebleeding and rebleeding from varices, in our meta-analysis. This is consistent with previous studies where TIPS was found to be more effective in preventing recurrent esophageal variceal bleeding in patients \[[@R32], [@R33], [@R34]\]. TIPS involves establishing a direct pathway between the hepatic and portal veins to decompress portal venous hypertension, which is the source of the patient\'s bleeding. Accordingly, TIPS is more than 90% effective in controlling bleeding from gastro-esophageal varices \[[@R11]\]. In our study, TIPS reduced mortality caused by bleeding, however, overall mortality was not significantly altered when compared to combination therapy. Holster et al. reported results consistent with this study \[[@R33]\], whereas a study by Garcia-Pagan et al. suggested a decrease in the risk of mortality with TIPS \[[@R29]\]. These contrasting results could be related to the patient follow-up or to the differing grades of cirrhosis inpatients. Sauer et al. demonstrated that TIPS did not improve survival rate associated with an increased risk of encephalopathy and high rates of shunt dysfunction \[[@R40]\]. There is an increase in the rate of development of hepatic encephalopathy after a TIPS procedure \[[@R13], [@R40], [@R41]\]. Conversely, other studies indicated that TIPS did not significantly increase the incidence of hepatic encephalopathy, compared other interventions \[[@R18], [@R27], [@R29], [@R37]\]. Although there is no consensus in these studies, TIPS is a widely accepted therapy as a result of extensive clinical validation in recent years. Based on Puente\'s study \[[@R42]\], we found that confounding factors including the Child score (Child C \>20% and Child C ≤20%) and follow-up time (\<15 months and≥15 months) weren\'t discovered to influence the results under in the case of the less number.

To our knowledge, TIPS insertion leads to important pathophysiologic circulatory changes; TIPS significantly reduces pressure in the extrahepatic portal venous system secondary to a dramatic drop in intrahepatic vascular resistance to portal flow; therefore, TIPS is potentially useful for patients with portal hypertension \[[@R43]\]. TIPS prevents rebleeding more effectively than drug treatment or endoscopic procedures alone, but it can cause encephalopathy and has no overall survival benefit \[[@R44]\]. Moreover, high-risk patients (those with advanced cirrhosis) experience less rebleeding and have an increased survival rate if TIPS is placed within five days of variceal bleeding \[[@R29], [@R44]\]. In this meta-analysis, we compare TIPS with combination therapy and show a significant reduction in mortality from variceal bleeding, although there was no overall improvement in survival when TIPS was used, which may be related to hepatic encephalopathy.

An advantage of this meta-analysis is that all included studies were randomized, controlled clinical trials and with large sample sizes \[[@R21]\], however, some limitations in our study should be addressed. Firstly, few clinical trials met the inclusion criteria, therefore, more clinical studies are required to confirm our results. Secondly, the double-blind methods of methodological quality of eligible trials could not be performed, due to the specificity of EVL and TIPS. In addition, heterogeneity of drug dose may also be a concern in our meta-analysis. Finally, the complications associated with TIPS, such as hepatic encephalopathy, are unclear in our study, which may exert influence on mortality.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

This systematic review and meta-analysis was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@R45]\] and conducted in accordance with the Cochrane Collaboration\'s systematic review framework \[[@R46]\]. We used the PubMed, EMBASE, and Cochrane Central databases to perform a literature search on articles published up until November 2016, using the following MeSH words and key terms: "esophageal varices", "variceal rebleeding", "variceal hemorrhage", "portal hypertension", "liver cirrhosis", "pharmacotherapy", "endoscopic variceal ligation", and "transjugular intrahepatic portosystemicshunt". We also searched the reference lists of the retrieved studies.

Literature selection and exclusion {#s4_2}
----------------------------------

The inclusion criteria for selection of clinical trials in to the meta-analysis were as follows: (1) randomized, controlled trials comparing pharmacotherapy plus EVL with EVL or pharmacotherapy alone, or TIPS; (2) study participants should be older than 16 years of age with at least one previous episode of esophageal bleeding; and (3) studies needed to have measured at least one of the following outcomes as their endpoints: overall mortality, mortality caused by variceal bleeding, recurrence of bleeding, or recurrence of bleeding from esophageal varices.

Studies comparing these outcomes in the primary prevention of gastroesophageal bleeding, those that included patients with gastric varices alone, or liver cancer, were excluded from our analysis. If that the study was a duplicate or study\'s data could not be extracted or obtained through contact with the author, were excluded.

Data extraction {#s4_3}
---------------

Data was extracted directly from the selected studies by two independent reviewers. In the case of disagreement, a third reviewer was consulted. The relevant information included study design, patient characteristics, interventions, controls, and four outcomes: overall mortality, mortality caused by variceal bleeding, recurrence of bleeding, and recurrence of bleeding from esophageal varices.

Quality assessment of included studies {#s4_4}
--------------------------------------

Two investigators independently evaluated the methodological quality of eligible trials using the Cochrane collaboration tool for assessing risk of bias \[[@R47]\] (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias).

Statistical analysis {#s4_5}
--------------------

This meta-analysis was performed using Stata 12.0. Dichotomous outcomes were expressed as relative risk (RR) with a 95% confidence interval (CI) \[[@R46], [@R48]\]. Heterogeneity between studies was also analyzed using chi-square tests, with the significance level set to P \<0.1 \[[@R49]\]. No heterogeneity is observed when I^2^ =0%. However, when I^2^ \>50%, studies were considered to have significant heterogeneity and a random-effects model was used to conduct the meta-analysis, whereas when I^2^ \<50%, a fixed-effects model was used instead \[[@R46]\].

The symmetry of a funnel plot was used to qualitatively determine whether there was publication bias \[[@R50]\]. In the funnel plot, larger studies that provide a more precise estimate of an interventions effect from the spout of the funnel, whereas smaller studies with less precision form the cone end of the funnel. Asymmetry in the funnel plot indicates potential publication bias, which is assessed by the Egger\'s test for a quantitative detection of bias \[[@R51]\].

Ethical approval {#s4_6}
----------------

Not required.

CONCLUSIONS {#s5}
===========

This meta-analysis indicated that a combined therapy of pharmacotherapy plus EVL was more effective in decreasing rebleeding than monotherapy. Furthermore, TIPS was superior to combined therapy in decreasing the risk of rebleeding, rebleeding from varices, and mortality caused by bleeding, although not overall mortality. Accordingly, we recommend TIPS for the prevention of variceal rebleeding in patients with cirrhosis.
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==========================================
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ISMN

:   isosorbide mononitrate
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